
Valiant Organics Q2 FY23 Earnings Call Analysis
Revenue, margin, capex, fundraise and order book outlook from management commentary.
Management growth scorecard
Revenue
Category 3
Margin
Category 3
Fundraise
N/A
Order
N/A
Capex
Yes
1 of 3 growth signals are positive — mixed outlook.
Full analysisRevenue guidance
Category 3- The company expects revenue growth of 5% to 10% for the current financial year (FY23), targeting INR 1,000 to 1,100 crores on a standalone basis.
- For FY24 and beyond, a growth of around 30% is anticipated with full ramp-up of PAP (para Aminophenol), OAP (other agrochemicals project), and pharma intermediates.
- Pharma intermediates plant expected to reach around 45-50% utilization in initial quarters of FY24 and full utilization by end of FY24, targeting about INR 50 crores revenue at full capacity.
- Continuous process for PAP expected to increase production capacity from 500 to 1,000 metric tons per month once technical challenges are resolved, likely in upcoming financial years.
- Volume recovery at Sarigam plant to full original levels (~4,000-4,500 tons per quarter) by Q4 FY23.
- Overall growth driven by stabilizing raw material prices, operational improvements, and new product launches.
See what Valiant Organics management said on margin guidance — free account, 30 seconds.
Fundraise plans
- There is no specific mention of any current or future fundraising through debt or equity in the provided transcript.
- The company has been focusing on capex projects funded internally, with an annual capex range of INR 80 to 100 crores.
- The management discussed ongoing capex for pharma intermediates (INR 60 crores) and OAP (INR 15 crores) but did not indicate raising funds through equity or debt.
- They mentioned managing working capital and improving cash flows post-Sarigam incident, with some reduction in short-term borrowing.
- No explicit plans for raising debt or equity were stated during the Q&A or management comments.
See what Valiant Organics management said on order book — free account, 30 seconds.
Capex plans
Yes- Ongoing capex includes INR 15 crores for OAP (Ortho Anisic Phenol) and INR 60 crores for pharma intermediates, totaling around INR 75 crores.
- Pharma intermediates capex is completed with trial runs done and awaiting government approvals (expected by end Q3 FY '23).
- OAP capex is still ongoing with trial runs and some additional capex expected.
- After commissioning these projects, further capex plans are unclear; typically, the company does INR 80-100 crores of annual capex.
- The company is also analyzing new product opportunities, potentially involving a modest capex of around INR 40-45 crores if successful.
- Focus remains on stabilizing current projects before launching new large investments.
- The pharma intermediates plant will be captive to Aarti Pharmalabs.
- Continuous development and trials ongoing to shift PAP production from batch to continuous process for efficiency gains.
Track Valiant Organics — get its next earnings analysis in your feed
How does Valiant Organics rank vs peers in Chemicals & Petrochemicals?
Pro featureHow does Valiant Organics rank in Chemicals & Petrochemicals?
Compare Valiant Organics against every Chemicals & Petrochemicals company (Q2 FY23) on revenue, margins and earnings-call signals.
Continue your research
What Valiant Organics's management said in earlier quarters
Others in Chemicals & Petrochemicals this season
- Seya Industries (Q2 FY27)
Revenue from Operations (Net) for the quarter ended September 30, 2026: ₹0 lakhs (no sales reported). Key results statement takeaways from Seya Industries Ltd's
- DCM Shriram Fine Chemicals (Q2 FY27)
9,622.39 lakhs for the quarter ended September 30, 2025, indicating a year-on-year decrease of approximately 7.8%. Key results statement takeaways from DCM Shri
- Dhariwalcorp (Q2 FY27)
For the half year ended September 30, 2026, consolidated revenue from operations is ₹23,640.36 lakhs, up from ₹17,767.97 lakhs in the previous comparable…
- Agastya Energy (Q2 FY27)
For the quarter ended 30th September 2026, the consolidated revenue from operations was ₹625.15 lakhs, down from ₹4410.2 lakhs in the same quarter last year…